AF recurrence in the 6-month post-ablation period (36% vs. 18%, respectively; p ¼ 0.04). However, they found no significant differences between pre-procedural ANP levels among responders with and without AF recurrence. The same was true for ANP levels of nonresponders with and without AF recurrence.
. Thus, reduction in LA size (or reverse remodeling), associated with improved atrial function, is considered a surrogate for treatment success (9, 10) . AF recurrence showed atrial volume reduction that was similar to that in patients who had no evidence of recurrence (12) . In the present study, Nakanishi et al. and Biotronik; and has served on advisory boards for Janssen Pharmaceuticals and Bristol-Myers Squibb. Dr. Lee has reported that she has no relationships relevant to the contents of this paper to disclose. [19] [20] [21] , and it may not be until fibrosis becomes quite extensive, at least one-third of the myocardium in one study, that lower BNP levels are seen (22) .
Another provocative finding in the present study is that pre-procedural ANP levels did not predict maintenance of sinus rhythm after ablation (even though ANP levels predicted LA reverse remodeling "responder" status, and being a "responder" pre- Appropriate patient selection is critical to maximizing the likelihood of ablation success in AF. Biomarkers hold promise in assisting with identification of patients most likely to benefit from this procedure, but much work remains before they can be properly implemented.
